Skip to main content
You have permission to edit this article.
Edit
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Heartbeam Inc (NQ: BEAT )

4.830 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 4.830
Bid (Size) 4.710 (5)
Ask (Size) 5.000 (1)
Prev. Close 4.830
Today's Range 4.830 - 4.830
52wk Range 1.120 - 6.740
Shares Outstanding 34,260,799
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Recognized for ‘Unique Approach to Heart Attack Diagnosis’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022
 
Via Benzinga

Performance

YTD
+31.61%
+31.61%
1 Month
+19.26%
+19.26%
3 Month
+289.52%
+289.52%
6 Month
+222.00%
+222.00%
1 Year
+16.53%
+16.53%

More News

Read More
New Research Finds Gaming Can Cause Fatal Arrhythmias
Via Investor Brand Network
HeartBeam Inc. (NASDAQ: BEAT) Announces New Chief Medical Officer
Via Investor Brand Network
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Via Benzinga
HeartBeam Inc. (NASDAQ: BEAT) Awarded Top Honors for Game-Changing Cardiovascular Tech Platform
Via Investor Brand Network
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Expands Growing Portfolio with Valuable New Patent
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
HeartBeam Snags New Patent For 12-Lead ECG Smartwatch-Based Monitor To Detect Heart Attacks
Via Benzinga
New HeartBeam Patent for 12-Lead Electrocardiogram (ECG) Smartwatch-based Monitor Intended for Detection of Heart Attacks and Complex Cardiac Arrhythmias
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q3 2022 Financial Report
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
HeartBeam Reports Third Quarter 2022 Financial Results
From HeartBeam, Inc.
Via Business Wire
Study Finds Covid-19 Spikes Linked to Increases in Heart Attacks
Via Investor Brand Network
Exposures COVID-19
Study Finds Smart Watches Can Accurately Detect Atrial Fibrillation
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q3 2022 Results Conference Call
Via Investor Brand Network
HeartBeam to Host Third Quarter 2022 Results Conference Call on Thursday November 10, 2022 at 4:30 p.m. Eastern Time
From HeartBeam, Inc.
Via Business Wire
BioMedNewsBreaks – HeartBeam Inc.’s (NASDAQ: BEAT) Patented Breakthrough Technology Poised to Disrupt ECG Patch Market
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Featured in BioWorld(TM) MedTech Article
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Virgin Orbit And 4 More Short Squeeze Stocks That Could Soar This Week — Including A Stock Moving Up 968 Positions
Via Benzinga
GLSI, AVTE: The Top 5 Short Squeeze Stocks to Watch This Week
Via InvestorPlace
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) to Participate at Upcoming LD Micro Main Event XV Conference
Via Investor Brand Network
HeartBeam to Present at LD Micro Main Event XV Conference
From HeartBeam, Inc.
Via Business Wire
Study Finds Coffee Consumption Reduces Risk of Cardiac Problems
Via Investor Brand Network
Why Norwegian Cruise Line Shares Climbed By Around 12%; Here Are 66 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.